Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
cotadutide multidose pen · 1 trial · 1 indication
To evaluate exposure following a single subcutaneous dose of cotadutide at each of 3 different sites of injection.
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | 100ug SC injection cotadutide in the upper arm on Day 1, in the lower abdomen on Day 8, and in the thigh on Day 15 |
| Sequence 2 | EXPERIMENTAL | 100ug SC injection cotadutide in the thigh on Day 1, in the upper arm on Day 8, and in the lower abdomen on Day 15 |
| Sequence 3 | EXPERIMENTAL | 100ug SC injection cotadutide in the lower abdomen on Day 1, in the thigh on Day 8, and in the upper arm on Day 15 |
| Sequence 4 | EXPERIMENTAL | 100ug SC injection cotadutide in the thigh on Day 1, in the lower abdomen on Day 8, and in the upper arm on Day 15 |
| Sequence 5 | EXPERIMENTAL | 100ug SC injection cotadutide in the lower abdomen on Day 1, in the upper arm on Day 8, and in the thigh on Day 15 |
| Sequence 6 | EXPERIMENTAL | 100ug SC injection cotadutide in the upper arm on Day 1, in the thigh on Day 8, and in the lower abdomen on Day 15 |
| Name | Type | Description |
|---|---|---|
| cotadutide multidose pen injection | COMBINATION_PRODUCT | SC injection in the upper arm |
Inclusion Criteria: 1. Healthy subjects aged 18 through 60 years (inclusive) at the time of screening. 2. Electronic and/or written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations. 3. BMI between 19 and 30 kg/m2 (inclus...
Cotadutide multidose pen is an investigational small molecule being developed for Type 2 Diabetes Mellitus. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied to evaluate its pharmacokinetics in patients with this condition.
Cotadutide multidose pen is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetic profile in patients with Type 2 Diabetes Mellitus.
Cotadutide multidose pen is in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing for Type 2 Diabetes Mellitus.
Cotadutide multidose pen has one completed Phase 1 clinical trial registered under NCT04091373. This study investigated the pharmacokinetics of a single dose administration of cotadutide in 36 participants with Type 2 Diabetes Mellitus. The trial was conducted in the United States and included healthy volunteers.
Cotadutide multidose pen is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Type 2 Diabetes Mellitus. The drug has completed one Phase 1 trial, but it has not yet been evaluated in later-stage trials or submitted for regulatory approval.